A declining trend in CRP and PCT levels within the first 48–72 h after initiating therapy is generally associated with better outcomes, while persistently elevated or rising levels suggest ongoing infection, treatment failure, or a complicated course [13,19]. The gene discussed is CALCA; the disease is infection.